MedCity News November 17, 2024
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
Success rates in drug research for common diseases is low, and one reason for that could be perspective. Science has approached each common disorder as a single disease affecting a large population of patients. But John Mendlein, executive chairman and interim CEO of startup Vesalius Therapeutics, says a deeper look reveals that a single disease is actually many different diseases, each one with different biology that can be analyzed and potentially targeted with a novel medicine.
Vesalius is...
Today's Sponsors
Today's Sponsor